BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,132 filers reported holding BAXTER INTL INC in Q2 2020. The put-call ratio across all filers is 0.74 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $2,387,000 | 0.0% | 29,769 | 0.0% | 0.02% | -48.6% |
Q4 2020 | $2,387,000 | -0.3% | 29,769 | 0.0% | 0.04% | -27.1% |
Q3 2020 | $2,394,000 | +0.3% | 29,769 | +7.4% | 0.05% | -11.1% |
Q2 2020 | $2,386,000 | +6.1% | 27,730 | 0.0% | 0.05% | -16.9% |
Q1 2020 | $2,248,000 | -3.0% | 27,730 | 0.0% | 0.06% | +18.2% |
Q4 2019 | $2,317,000 | -4.4% | 27,730 | 0.0% | 0.06% | -14.1% |
Q3 2019 | $2,424,000 | +6.8% | 27,730 | 0.0% | 0.06% | +4.9% |
Q2 2019 | $2,270,000 | +0.7% | 27,730 | 0.0% | 0.06% | -4.7% |
Q1 2019 | $2,255,000 | +23.6% | 27,730 | 0.0% | 0.06% | +10.3% |
Q4 2018 | $1,825,000 | -22.0% | 27,730 | -8.6% | 0.06% | +3.6% |
Q3 2018 | $2,340,000 | +4.4% | 30,349 | 0.0% | 0.06% | +1.8% |
Q2 2018 | $2,241,000 | +13.5% | 30,349 | 0.0% | 0.06% | +7.8% |
Q1 2018 | $1,974,000 | +0.6% | 30,349 | 0.0% | 0.05% | +2.0% |
Q4 2017 | $1,962,000 | +3.0% | 30,349 | 0.0% | 0.05% | -3.8% |
Q3 2017 | $1,904,000 | -99.9% | 30,349 | +24.2% | 0.05% | +23.8% |
Q2 2017 | $1,478,990,000 | -83.1% | 24,434 | -80.5% | 0.04% | -82.6% |
Q2 2015 | $8,742,191,000 | -1.7% | 125,085 | -3.7% | 0.24% | +3.4% |
Q1 2015 | $8,891,854,000 | – | 129,846 | – | 0.23% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |